Dr. Janet Dancey appointed to second term as Director, Canadian Cancer Trials Group & Edith and Carla Eisenhauer Chair in Clinical Cancer Research
Dean Richard Reznick is pleased to announce that Tom Harris, Interim Provost and Vice-Principal (Academic) at Queen’s University, has appointed Dr. Janet Dancey to a second term as Director, Canadian Cancer Trials Group (CCTG), and the Edith and Carla Eisenhauer Chair in Clinical Cancer Research. The re-appointment in both roles is effective September 1, 2019 through to June 30, 2024.
Dr. Dancey earned her Bachelor of Medical Science and her MD from the University of Ottawa, and completed residencies in Internal Medicine (1991) and Medical Oncology (1993) at the University of Toronto. Dr. Dancey first came to Queen’s in 1994 as a clinical research fellow of the National Cancer Institute of Canada Clinical Trials Group before completing a post-graduate research fellowship at the Institut Gustave Roussy in France. Dr. Dancey has held positions at the US National Cancer Institute, including Senior Clinical Investigator and Associate Chief, Investigational Drug Branch of the Cancer Therapy Evaluation Program, and prior to her initial appointment as Director, CCTG, she served as Director of the High Impact Clinical Trials Program at the Ontario Institute for Cancer Research from 2008-2015.
A recognized leader within Queen’s and the international research community, Dr. Dancey serves as the Scientific Director of the Canadian Cancer Trials Network (3CTN) and Senior Investigator for the Melanoma Disease Site Committee. She is a Professor in the Department of Oncology, Faculty of Health Sciences, and represents Queen’s, CCTG and 3CTN on various national and international advisory boards. She is currently serving as Chief or Principal Investigator over grant-funded research supported by the National Health and Medical Research Council, National Institute of Health, and CIHR for advancement in the research and treatment of metastatic melanoma, establishment of stronger collaboration among clinical trials agencies, and incorporation of new technology in cancer treatment.
CCTG has had unparalleled growth in the last five years, and is widely considered one of the preeminent trials groups in the world. During her first term as Director, CCTG, Dr. Dancey was key in securing more than $33M in funding for CCTG innovations. Two trials in survival rates and quality of life for treatment of glioblastoma were recognized as having top research impact by the Canadian Cancer Society. Dr. Dancey is passionate about the positive impact of collaboration on advancing cancer research and under her tenure as Director the CCTG fosters a national and international culture of interest in collaborative research with 40 countries. Eagerly imparting her expertise and experience as a faculty member and a mentor of clinical trainees, she embodies commitment to furthering medical innovations today and the medical innovators of tomorrow.
Please join the Dean in thanking Dr. Dancey for her continued commitment to Queen’s University and the CCTG.